Stay updated on TrkA Inhibitor VMD-928 Clinical Trial
Sign up to get notified when there's something new on the TrkA Inhibitor VMD-928 Clinical Trial page.

Latest updates to the TrkA Inhibitor VMD-928 Clinical Trial page
- Check4 days agoChange DetectedA new Revision: v3.3.3 entry has been added to the Record History. The HHS Vulnerability Disclosure link and Revision: v3.3.2 entry were removed.SummaryDifference0.2%

- Check11 days agoChange DetectedThe study title was updated from 'Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma' to 'VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma'. The record also updated/added several sections including Eligibility, Outcome Measures, Arms and Interventions, Study Design, Conditions, Study Description, Study Status, and Study Identification.SummaryDifference0.9%

- Check19 days agoNo Change Detected
- Check26 days agoChange DetectedA new revision entry (v3.3.2) was added to the history and the previous revision (v3.3.1) was removed.SummaryDifference0.1%

- Check33 days agoChange DetectedThe history now lists a new revision entry v3.3.1 and removes the previous v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check40 days agoChange DetectedDeleted a site-wide notice about government funding and operating status; no study data or record content was changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

- Check54 days agoChange DetectedRecord history now includes new versions documenting updates to study status, contacts/locations, and other core study details.SummaryDifference0.1%

Stay in the know with updates to TrkA Inhibitor VMD-928 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TrkA Inhibitor VMD-928 Clinical Trial page.